Edition:
United States

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

6.50USD
14 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.50
Open
$6.50
Day's High
$6.65
Day's Low
$6.50
Volume
6,864
Avg. Vol
117,818
52-wk High
$11.90
52-wk Low
$3.80

Latest Key Developments (Source: Significant Developments)

Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data
Wednesday, 29 Nov 2017 08:00am EST 

Nov 29 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING.  Full Article

Aldeyra Therapeutics reports Q3 loss per share of $0.32
Thursday, 9 Nov 2017 07:30am EST 

Nov 9 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.32.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.‍Cash, cash equivalents, and marketable securities were $47.9 million as of September 30, 2017​.  Full Article

Aldeyra ‍announcesd new data for ADX-102 from Phase 2 clinical trials
Tuesday, 10 Oct 2017 07:30am EDT 

Oct 10 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra - ‍announced new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis​.Aldeyra Therapeutics Inc - ‍Aldeyra plans to commence phase 2B clinical testing of ADX-102 in dry eye disease in first half of 2018​.Aldeyra Therapeutics Inc - ‍ADX-102 generated clinically important responses statistically superior to vehicle in patients with allergic conjunctivitis​.Aldeyra Therapeutics Inc - ‍plans to commence Phase 3 clinical testing of ADX-102 in allergic conjunctivitis in first half of 2018​.  Full Article

Aldeyra Therapeutics posts pricing of public offering of common stock
Tuesday, 19 Sep 2017 08:57am EDT 

Sept 19 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics Inc announces pricing of public offering of common stock.Says public offering of 3.45 mln common shares priced at $7.25 per share.  Full Article

Aldeyra Therapeutics announces proposed public offering of common stock
Monday, 18 Sep 2017 04:01pm EDT 

Sept 18 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics Inc announces proposed public offering of common stock.Aldeyra Therapeutics - To offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering​.Aldeyra Therapeutics Inc says ‍net proceeds to be used for continued development of Aldeyra's lead compound ADX-102 and other product candidates​.  Full Article

Aldeyra Therapeutics announces positive results from dry eye disease phase 2a clinical trial
Tuesday, 12 Sep 2017 07:01am EDT 

Sept 12 (Reuters) - Aldeyra Therapeutics Inc ::Aldeyra Therapeutics announces positive results from dry eye disease phase 2a clinical trial.Aldeyra Therapeutics says statistically and clinically significant improvement across multiple sign and symptom endpoints for ADX-102.Aldeyra Therapeutics says no safety concerns observed for any of the formulations of ADX-102, no serious adverse events were reported.Aldeyra Therapeutics says look forward to initiation of phase 2b clinical trial in dry eye disease in H1 of 2018.  Full Article

Aldeyra Therapeutics announces positive results from dry eye disease phase 2A clinical trial
Tuesday, 12 Sep 2017 07:01am EDT 

Sept 12 (Reuters) - Aldeyra Therapeutics Inc ::Aldeyra Therapeutics announces positive results from dry eye disease phase 2A clinical trial.  Full Article

Aldeyra Therapeutics Q2 loss per share $0.35
Tuesday, 8 Aug 2017 07:30am EDT 

Aug 8 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra therapeutics announces second quarter 2017 financial results.Q2 loss per share $0.35.Q2 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S.Aldeyra therapeutics inc - ‍ data from phase 2a clinical trial in dry eye disease expected to be announced in september 2017​.  Full Article

Aldeyra Therapeutics says last patient dosed in dry eye disease phase 2a clinical trial
Tuesday, 18 Jul 2017 08:00am EDT 

July 18 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics announces last patient dosed in dry eye disease phase 2a clinical trial.Aldeyra Therapeutics Inc - ‍look forward to providing data from trial later this quarter​.  Full Article

Aldeyra Therapeutics expects to report results from phase 2A trial of topical ocular ADX-102 late in Q3
Thursday, 15 Jun 2017 05:27pm EDT 

June 15 (Reuters) - Aldeyra Therapeutics Inc ::Aldeyra Therapeutics-expects to report results from phase 2a trial of topical ocular ADX-102 late in Q3, 2017, not early in Q3 as stated in conf call.  Full Article

BRIEF-Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data

* ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING Source text for Eikon: Further company coverage: